Waltham, Massachusetts-based Thermo Fisher Scientific Inc. (TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, laboratory products and biopharma services. Valued at $218.2 billion by market cap, the company provides a portfolio of reagents, instruments, and consumables for research, drug development, and disease diagnosis, along with laboratory products and biopharma services. The leading scientific research services and products provider is expected to announce its fisca ...

Core Insights - Thermo Fisher Scientific Inc. (TMO) is a leading provider of life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products, with a market cap of $220.3 billion [1] Performance Overview - TMO shares have underperformed compared to the broader market, gaining 8.7% over the past year, while the S&P 500 Index has increased by nearly 14.5% [2] - In 2025, TMO stock is up 13%, compared to the S&P 500's 16.5% rise year-to-date [2] Sector Comparison - TMO has outperformed the Health Care Select Sector SPDR Fund (XLV), which gained about 3.8% over the past year, and TMO's year-to-date gains surpass the ETF's 11.1% returns [3] Market Challenges - TMO's underperformance is attributed to economic weakness in China, pricing pressures, and cautious spending by academic institutions and governments [4] - Diagnostics in China are struggling, while Europe shows modest improvement, and the U.S. market remains stable but uncertain [4] Financial Performance - On October 22, TMO reported Q3 results, with an adjusted EPS of $5.79, exceeding Wall Street expectations of $5.50, and revenue of $11.1 billion, beating forecasts of $10.9 billion [5] - For the current fiscal year ending in December, analysts expect TMO's EPS to grow by 4% to $22.74 on a diluted basis [5] - TMO has a strong earnings surprise history, beating consensus estimates in each of the last four quarters [5] Analyst Ratings - Among 23 analysts covering TMO, the consensus rating is a "Strong Buy," with 16 "Strong Buy" ratings, two "Moderate Buys," and five "Holds" [6] - This rating configuration is less bullish than a month ago, when 17 analysts suggested a "Strong Buy" [7]